If you've been curious about weight loss medications but feel overwhelmed by all the options, you're not alone. With so many ...
New 7.2 mg Wegovy dose launches Tuesday at lower cash price as Novo targets stronger efficacy and broader access.
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...
The FDA has approved Foundayo, a new weight-loss pill that could give Eli Lilly an edge over other drugmakers. Here's how it ...
Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill ...
From Zepbound to cancer care, insurance denials are up in 2026. Even with good insurance, consumers face steep bills for ...
Adverse events in participants treated with concomitant administration of Taltz and Zepbound were generally mild to moderate, and the types of adverse events were consistent with the known safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results